Yan Peng, M.D., Ph.D.
Associate Professor

Dr. Yan Peng completed her Pediatric Residency/Chief Resident at Beijing Medical University Hospitals and practiced there as a Pediatric Nephrologist for two years. After a combined six years of basic research on kidney disease at Mayo Clinic and Foundation and UT-Southwestern Medical Center (UTSW), she went to University of Pittsburgh Medical Center (UPMC) for Pathology Residency. Upon the completion, she took two fellowship trainings in Breast and Gynecologic Pathology and Cytopathology at UPMC and Harvard Medical School, respectively.

She has been a Breast and Gynecologic Surgical Pathologist and Cytopathologist at the UTSW. She is the Pathology Liaison at Cancer Committee of UTSW Simmons Cancer Center and University Hospital. She  served as Medical Directors of Diagnostic Immunohistochemistry Laboratory and Tumor Biomarker Image Analysis Laboratory for about 10 years. As co-investigator, she has participated in more than 30 National Cancer Institute (NCI) Breast and Gynecologic cancer clinical trials. She has served as an investigator for NCI Cancer Therapy Evaluation Program since 2014.

She has published more than 70 peer-reviewed articles and served as an editorial board member for multiple scientific journals including Human Pathology. 

Medical School

Beijing Medical University (1986)

Residency

Beijing University Hospital (1989), Pediatrics

Graduate School

Beijing Medical University (1991)

Fellowship

Mayo Clinic (1995), Physiology

Fellowship

UT Southwestern Medical Center (1999), Molecular Nephrology Research

Residency

University of Pittsburgh Medical Center (2003), Anatomic & Clinical Pathology

Fellowship

University of Pittsburgh Medical Center Magee Womens Hospital (2004), Breast & Gynecologic Pathology

Fellowship

Harvard Medical School/Beth Israel Deaconess Medical Center (2005), Cytopathology

• Breast Cancer and Gynecologic Cancer Pathology
• Diagnostic Immunohistochemistry: Theranostic and Genomic Applications
• Prognostic and predictive tumor biomarkers

Featured Publications

ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.

Chen Y, Zhang B, Bao L, Jin L, Yang M, Peng Y, Kumar A, Wang JE, Wang C, Zou X, Xing C, Wang Y, Luo W J. Clin. Invest. 2018 May 128 5 1937-1955

Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.

Yang C, Sun L, Zhang L, Zhou L, Zhao M, Peng Y, Niu D, Li Z, Huang X, Kang Q, Jia L, Lai J, Cao D Am. J. Surg. Pathol. 2017 Sep

Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.

Wu H, Bi J, Peng Y, Huo L, Yu X, Yang Z, Zhou Y, Qin L, Xu Y, Liao L, Xie Y, Conneely OM, Jonkers J, Xu J Oncotarget 2017 Aug 8 33 54364-54377

KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.

Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chlopik A, Marti GT, Paral K, Shalin S, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP Br. J. Dermatol. 2017 Jul

Update on Immunohistochemical Analysis in Breast Lesions.

Peng Y, Butt YM, Chen B, Zhang X, Tang P Arch. Pathol. Lab. Med. 2017 Jun

Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.

Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK Breast Cancer Res. Treat. 2015 Mar

Quantification of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Using the Ventana Image Analysis System: Correlation With Gene Amplification by Fluorescence In Situ Hybridization: The Importance of Instrument Validation for Achieving High (>95%) Concordance Rate.

Dennis J, Parsa R, Chau D, Koduru P, Peng Y, Fang Y, Sarode VR Am. J. Surg. Pathol. 2015 Jan

Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma (TNBC): comparison with GATA3 expression and PELP1's potential role in TNBC

Dang D, Raj G, Sarode V, Molberg K, Vadlamudi R and Peng Y* humpath. 2015 46 12 1829-1835

KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer.

Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, Peng Y, John GB, Li HC, Sadeghi N, Wright WE, Lum L, Corson TW, Shay JW Neoplasia 2014 Mar 16 3 247-256.e2

Cutaneous and mammary apocrine carcinomas have different immunoprofiles.

Piris A, Peng Y, Boussahmain C, Essary LR, Gudewicz TM, Hoang MP Hum. Pathol. 2014 Feb 45 2 320-6

 Featured Books

Invasive Breast Carcinomas. In Peng Y, Kong C, and Chen Y. Practical Breast Pathology. Atkins K and Kong C (eds.), a volume in the Pattern Recognition Series. Kevin O. Leslie and Mark R.Wick (eds.).

Peng Y, Kong C, and Chen Y. (2013; 147-212). Philadelphia, PA, Elsevier

• Chair, Pathology Faculty Mentoring Committee
  (2017)
• Member, Abstract Review Board of United States and Canadian Academy of Pathology (Breast Pathology Category)
  (2017-2020)
• Member, UT Southwestern Medical School Dean’s Standing Committee (Faculty Council and LCME)
  (2017)
• President, International Association of Chinese Pathologists (IACP)
  (2017-2018)
• President, UT Southwestern Faculty Senate
  (2017-2018)
• President-Elect, North Texas Society of Pathologists (NTSP)
  (2017)
• Distinguished Young Investigator Award in Medicine
  Beijing, China (1993)
• Distinguished Scientist Award of Canada China Child Health Foundation
  (1992)
• Best National Medical Article Award
  China (1991)
•